Patient preferences for ITP treatment
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living in the United States.
- You must be 18 years or older.
- You must have been diagnosed with primary immune thrombocytopenia (ITP).
- If you are in first-line treatment, you must have started corticosteroids within 3 months of diagnosis and responded to them.
- If you are in second-line treatment, you must need or be taking a TPO-RA and have previously had an insufficient response to corticosteroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This study looks at how people with immune thrombocytopenia (ITP) are treated in real life. It aims to understand which treatments work best for patients who have had ITP for up to 12 months.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.